【NEWS】Cyto-Facto Signs Memorandum of Understanding with Merck
2026/03/11
Cyto-Facto Inc. has signed a Memorandum of Understanding (MoU) with Merck, a leading science and technology company, to support the advancement of cell and gene therapy (CGT) development and manufacturing. Through this collaboration, Merck’s innovative technologies and global expertise will be combined with Cyto-Facto’s specialized CGT manufacturing capabilities to help strengthen gene therapy development and manufacturing platforms in the Asia-Pacific region.
For more details, please refer to the full press release published by Merck.
https://www.merckgroup.com/in-en/company/media.html
https://www.merckgroup.com/in-en/Press-Releases/2026/PR-MOU-with-Cyto%20Facto-Merck%20India.pdf